Jialan Zang
Jiangsu Cancer Hospital(CN)Second Affiliated Hospital of Nanjing Medical University(CN)Nanjing Medical University(CN)
Publications by Year
Research Areas
MicroRNA in disease regulation, Lung Cancer Treatments and Mutations, Cancer-related molecular mechanisms research, Cytokine Signaling Pathways and Interactions, NF-κB Signaling Pathways
Most-Cited Works
- → Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin(2017)30 cited
- → Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer(2017)19 cited
- → Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation(2017)18 cited
- → Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro(2017)16 cited
- → MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment(2017)11 cited
- → [Relationship of clusterin expression with Bax and p53 expression in non-small cell lung cancer].(2007)4 cited